18F-FDG PET显像在胰腺癌诊断中的临床应用

目的：探讨^18F-FDG PET显像在胰腺癌诊断中的应用价值。方法：54例临床怀疑为胰腺癌的患者均行^18F-FDG PET显像,对显像结果进行目测法及半定量分析,并与CT、手术、腹腔镜取病理等进行对比研究。结果：^18F-FDG PET显像对胰腺癌诊断的敏感度为93％(38／41),特异度为85g(11／13)。CT对胰腺癌诊断的敏感度为76N(31／41),特异度为69％(9／13)。^18F-FDG PET显像发现7例CT检查未能确定的肝、肺及淋巴结转移,同时PET诊断结果使15例(28％)患者的临床治疗方案得到修正。结论：^18F-FDG PET显像对胰腺癌的诊断及临床分期具有较好的临床应用价值。     

~(18)F-FDG PET显像诊断胆囊癌

目的：探讨^18F-FDG PET显像在胆囊癌诊断中的应用价值。方法：7例临床怀疑的胆囊癌患者均行^18F—FDG PET显像，对显像结果进行目测法及半定量分析，并与CT、手术、腹腔镜取病理等进行对比研究。结果：病理检查确诊4例胆囊癌，3例胆囊良性病变。^18F-FDG PET显像均正确定性。CT对6例作出正确定性。2例PET显像发现了CT未发现的转移灶3处，并对1例胆囊癌患者进行了正确疗效评价。结论：^18F-FDG PET显像对胆囊癌的诊断及临床分期具有较好的临床应用价值，并可准确地评价治疗效果。     

18氟-脱氧葡萄糖和11碳-乙酸PET/CT显像在原发性肝癌及肝脏肿瘤样病变诊断中的初步研究

目的探讨18氟-脱氧葡萄糖(18 F-fluorodexyoxyglucose,18F-FDG)和11碳-乙酸(11 C-acetate,11 C-ACT)PET/CT显像在原发性肝癌及肝脏肿瘤样病变诊断中的作用。方法回顾性分析9例患者资料,其中男性7例,女性2例,平均年龄70.2岁,所有患者均为肝内单发病灶。治疗前均先行18 F-FDG PET/CT,后行11 C-ACT PET/CT检查,两次检查间隔时间不超过1周。其中有7例肝细胞肝癌(hepatocelluar carcinoma,HCC)、1例胆管细胞癌(cholangiocarcinoma,CCC)、1例肝内感染性病灶,均经病理学或临床随访证实。结果 7例HCC患者18 F-FDG PET/CT显像均为阴性,11 C-ACT PET/CT显像有6例为阳性。18F-FDG PET/CT和11 C-ACT PET/CT显像均未发现1例高分化胆管细胞癌。对于1例肝内炎性病灶,18F-FDG PET/CT显像为阳性,而11 C-ACT PET/CT显像为阴性。结论①11 C-ACT PET/CT显像可以用来探测那些呈18 F-FDG等或低摄取的HCC病灶;②对于高分化的CCC,18 F-FDG PET/CT显像有可能会表现为假阴性结果;③11 C-ACT PET/CT显像可以用来诊断肝内感染性病灶。     

18F-FDG和18F-FET PET脑显像诊断垂体腺瘤

目的 比较^18F-脱氧葡萄糖(FDG)和^18F-酪氨酸(FET)PET显像对垂体腺瘤的诊断价值。方法 正常对照者7例同期行^18F-FDGPET脑显像和^13N-NH3PET脑血流显像。20例垂体腺瘤患者行^18F-FDG PET脑显像，其中10例同期行^18F-FETPET脑显像，并参照近期MRI结果进行分析。加例患者均行经口鼻蝶窦垂体腺瘤切除术，术后行病理检查及免疫组织化学分型。结果①正常对照组垂体^18F-FDG摄取明显低于周围组织。②对于分泌激素和无分泌功能的垂体腺瘤，^18F-FDGPET和^18F-FETPET均可显示病灶。③垂体腺瘤在^18F-FDG显像中多表现为均匀的放射性摄取增高，而^18F-FET。显像则多表现为散在的摄取增高，与MRI所示等瓦长T2或稍长瓦长T2信号的肿瘤组织分布相似。④7例微腺瘤^18F-FDG PET检出5例，MRI检出3例。⑤不同激素分泌型和无分泌功能垂体腺瘤的瘤体大小、激素水平与^18F-FDG或^18F-FET显像标准摄取值(SUV)间无明显相关。结论 ^18F-FDG和^18F-FET PET脑显像均可显示垂体腺瘤,而以前者更佳。     

^18F-FDG PET／CT及增强CT诊断原发性肝癌及肝癌术后复发的价值

目的比较^18F-脱氧葡萄糖（FDG）PET／CT与增强CT对原发性肝癌或肝癌术后复发的诊断价值。方法回顾性分析诊断为原发性肝癌或肝癌术后复发且进行^18F-FDG PET／CT与增强CT检查的病例共25例,2种检查间隔时间在1周内。其中原发性肝癌经手术或穿刺证实,肝癌术后复发经临床随访证实。结果25例患者中,确诊为原发性肝癌14例,其中肝细胞肝痛13例,胆管细胞癌1例;肝癌术后复发11例。^18F-FDG PET／CT对原发性肝癌的诊断阳性率为78．6％（11／14）,增强CT阳性率为92．9％（13／14）。在肝癌术后复发中,^18F-FDGPET／CT诊断阳性牢为100．0％（11／11）,增强CT阳性率为63．6％（7／11）。结论在原发性肝癌诊断中,增强CT优于^18F-FDG PET／CT,^18F-FDG PET／CT显像联合增强CT可明显提高诊断率。而在肝癌术后复发检测中,^18F-FDG PET／CT优于增强CT。     

~(18)F-FDG PET/CT对不明原因发热病因的诊断价值

目的：探讨^18F-脱氧葡萄糖（FDG）PET/CT显像对不明原因发热（FUO）的影像学表现及病因诊断价值。方法：回顾性分析常规检查未能明确诊断FUO病因的45例患者^18F-FDG PET/CT显像资料,根据病理检查或临床随访结果分析^18F-FDG PET/CT显像结果,测量异常摄取病灶最大标准摄取值（SUVmax）。采用SPSS 11.0软件进行数据处理,SUVmax两样本均数比较采用t检验。结果：45例患者中35例^18F-FDG PET/CT全身显像发现至少有1处异常放射性浓聚灶,随访证实其中9例为恶性肿瘤,26例为感染或炎性病变,二者病变的SUVmax分别为6.09±1.46和2.57±1.33,差异有显著性意义（t=6.67,P〈0.05）;10例^18F-FDG PET/CT显像阴性患者,6例病因不明,4例为风湿性疾病。^18F-FDGPET/CT显像有助于临床FUO病因诊断。结论：全身^18F-FDG PET/CT显像在其它检查方法未能明确诊断FUO病因时,可为临床进一步诊断提供重要的参考价值。     

核素显像在肝癌临床诊断中的应用

核素显像方法(包括SPECT、PET及PET／CT)对于原发性肝癌的诊断、良恶性鉴别及分化程度的评估有重要价值，尤其是^18F-FDG(^18F-氟代脱氧葡萄糖)PET及^11C-乙酸盐PET在评价肿瘤分化程度的作用优于CT、MRI。PET／CT的应用也将弥补PET在空间分辨率上存在的不足．提高肝癌诊断的准确性。     

18F-FDG PET/CT显像在原发性乳腺肿瘤鉴别诊断中的应用

目的探讨^18F-脱氧葡萄糖(FDG)PET／CT显像鉴别诊断乳房肿块良恶性的临床价值。方法乳房肿块患者34例，按体重5．55MBq/kg静脉注射^18F-FDG后40min行胸部俯卧位PET／CT显像，必要时加做3h延迟显像。经衰减校正后以半定量分析法[测定病灶的标准摄取值(SUV)及靶组织/非靶组织比值(T/NT)]及目测法进行图像分析，并与病理检查结果对照。结果手术病理检查证实乳腺癌27例，良性病变7例。^18F-FDG PET／CT显像目测法对乳房肿块良恶性鉴别的灵敏度为92．59％，特异性为6／7例，阳性预测值为96．15％。结论^F-FDG PET／CT显像是目前鉴别诊断乳房肿块性质较好的无创性检查方法。     

18F-FDG PET/CT在黑色素瘤中的应用价值

目的 探讨18F-脱氧葡萄糖(FDG)PET/CT显像在黑色素瘤诊断、临床分期及监测治疗后肿瘤复发与转移灶中的应用价值.方法 黑色素瘤患者61例,均进行18F-FDG PET/CT全身显像.所有PET、CT及PET/CT融合图像均通过融合软件进行帧对帧对比分析.肿瘤病灶根据病理学检查、多种影像学检查及临床随访结果诊断.结果 18F-FDG PET/CT显像对黑色素瘤病灶检出的灵敏度、特异性和准确性分别为90.9%(40/44)、88.2%(15/17)和90.2%(55/61).其中12例治疗前患者中,18F-FDG PET/CT显像诊断的灵敏度为83.3%(10/12).在黑色素瘤病灶局部切除、尚未进行其他治疗的9例患者中,5例残余病灶18F-FDG PET/CT显像检出3例;4例远处转移灶患者全被检出,提高了临床分期,改变了治疗方案.首先发现转移性黑色素瘤病灶并且手术切除后,寻找原发灶的7例患者中,18F-FDG PET/CT检出原发灶2例,4例其他转移灶全被检出.黑色素瘤患者根治术后监测肿瘤复发或转移患者33例,18F-FDG PET/CT显像灵敏度、特异性和准确性分别为100.0%(19/19)、85.7%(12/14)和93.9%(31/33).与同期临床其他影像学检查比较,18F-FDG PET/CT显像发现更多,33例患者中,16例(48.5%)病灶提高临床分期;7例(21.2%)排除可疑病灶,降低临床分期;10例(30.3%)检出病灶与临床一致.结论 18F-FDG PET/CT显像对于黑色素瘤的诊断,残余病灶、复发病灶及转移灶的检出,临床分期的明确具有重要价值.     

双时相^18F-FDG PET在肿瘤良恶性鉴别诊断中的应用

^18F-FDG PET已较广泛地用于对恶性肿瘤的诊断和临床分期。常规显像一般用单次显像所测SUV(标准化摄取值)来鉴别良恶性病变，但两者SUV之间有一定交叉，存在一定局限性。而依据不同类型细胞^18F-FDG摄取速率不同的机制，进行双时相^18F-FDG PET(早期显像加延迟显像)，简单而实用，具有较高的灵敏度、特异性和准确性。     

Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods

The aim of this study was to evaluate the usefulness of 18F-FDG PET in the diagnosis and staging of primary and recurrent malignant head and neck tumours in comparison with conventional imaging methods [including ultrasonography, radiography, computed tomography (CT) and magnetic resonance imaging (MRI)], physical examination, panendoscopy and biopsies in clinical routine. A total of 54 patients (13 female, 41 male, age 61.3+/-12 years) were investigated retrospectively. Three groups were formed. In group I, 18F-FDG PET was performed in 15 patients to detect unknown primary cancers. In group II, 24 studies were obtained for preoperative staging of proven head and neck cancer. In group III, 18F-FDG PET was used in 15 patients to monitor tumour recurrence after radiotherapy and/or chemotherapy. In all patients, imaging was obtained at 70 min after the intravenous administration of 180 MBq 18F-FDG. In 11 of the 15 patients in group I, the primary cancer could be found with 18F-FDG, yielding a detection rate of 73.3%. In 4 of the 15 patients, CT findings were also suggestive of the primary cancer but were nonetheless equivocal. In these patients, 18F-FDG showed increased 18F-FDG uptake by the primary tumour, which was confirmed by histology. One patient had recurrence of breast carcinoma that could not be detected with 18F-FDG PET, but was detected by CT. In three cases, the primary cancer could not be found with any imaging method. Among the 24 patients in group II investigated for staging purposes, 18F-FDG PET detected a total of 13 local and three distant lymph node metastases, whereas the conventional imaging methods detected only nine local and one distant lymph node metastases. The results of 18F-FDG PET led to an upstaging in 5/24 (20.8%) patients. The conventional imaging methods were false positive in 5/24 (20.8%). There was one false positive result using 18F-FDG PET. Among the 15 patients of group III with suspected recurrence after radiotherapy and/or chemotherapy, 18F-FDG was true positive in 7/15 (46.6%) and true negative in 4/15 (26.6%). The conventional imaging methods were true positive in 5/15 (33.3%) and true negative in 4/15 (26.6%). One false negative (6.6%) and three false positive findings (20%) on 18F-FDG PET were due to inflamed tissue. The conventional imaging methods were false positive in three (20%) and false negative in three cases (20%). It is concluded that in comparison to conventional diagnostic methods, 18F-FDG PET provides additional and clinically relevant information in the detection of primary and metastatic carcinomas as well as in the early detection of recurrent or persistent head and neck cancer after radiotherapy and/or chemotherapy. 18F-FDG PET should therefore be performed early in clinical routine, usually before CT or MRI.     

Recommendations on the use of 18F-FDG PET in oncology.

The rationale was to develop recommendations on the use of (18)F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. METHODS: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of (18)F-FDG PET on the management of cancer patients, were also reviewed. Results and CONCLUSION: (18)F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. (18)F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, (18)F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.     

18F-氟脱氧葡萄糖PET及PET-CT在食管癌中的应用价值

食管癌的预后较差,切除术的致死率和致残率较高,术前正确分期对确定治疗方案尤为重要。PET是对CT、MRI、食管镜等常规检查的有益补充。受分辨率的影响,PET较难确定肿瘤的浸润程度,但对远处转移灶的诊断明显优于CT、MRI等常规检查,诊断复发性食管癌准确率较高,能有效鉴别手术瘢痕和复发,有效评价放疗、化疗的疗效。结合传统影像学检查,18F-氟脱氧葡萄糖PET及PET-CT能较为准确地进行术前分期,纠正不正确的治疗方案,改善食管癌患者的预后。     

18F-FDG PET/CT在不明原发灶肿瘤中的临床应用价值

目的探讨18F-FDG PET/CT全身显像在不明原发灶肿瘤（CUP）诊断中的临床应用价值。方法回顾分析46例于2015年2月至2016年6月在我院行常规检查未能发现肿瘤原发灶而进一步行18F-FDG PET/CT全身显像查找肿瘤原发灶的转移性肿瘤患者的资料。PET/CT图像分析采用视觉及半定量分析方法。通过病理活检和（或）临床综合诊断、临床随访对结果进行评价。结果46例患者中,18F-FDG PET/CT显像找到原发肿瘤33例,均经过病理活检及临床随访证实;13例未发现原发病灶。18F-FDG PET/CT对不明肿瘤原发灶的检出率为71.7%（33/46）,其中阳性患者中淋巴瘤3例、胃癌2例、食管癌4例、卵巢癌3例、肺癌14例、肝癌2例、尿路上皮癌1例、鼻咽癌2例、多发性骨髓瘤1例、降结肠癌1例。转移方式主要有淋巴结转移32例、骨转移20例、肝转移13例、肺转移9例、胸膜腹膜转移5例、肾上腺转移3例、脑转移4例、皮下转移3例、心包膜转移1例。结论18F-FDG PET/CT全身显像对CUP的检出率显著优于一般常规检查,对临床指导治疗有着重要意义。     

Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods

The aim of this study was to evaluate the usefulness of ¹⁸F-FDG PET in the diagnosis and staging of primary and recurrent malignant head and neck tumours in comparison with conventional imaging methods [including ultrasonography, radiography, computed tomography (CT) and magnetic resonance imaging (MRI)], physical examination, panendoscopy and biopsies in clinical routine. A total of 54 patients (13 female, 41 male, age 61.3ᆠ years) were investigated retrospectively. Three groups were formed. In group I, ¹⁸F-FDG PET was performed in 15 patients to detect unknown primary cancers. In group II, 24 studies were obtained for preoperative staging of proven head and neck cancer. In group III, ¹⁸F-FDG PET was used in 15 patients to monitor tumour recurrence after radiotherapy and/or chemotherapy. In all patients, imaging was obtained at 70 min after the intravenous administration of 180 MBq ¹⁸F-FDG. In 11 of the 15 patients in group I, the primary cancer could be found with ¹⁸F-FDG, yielding a detection rate of 73.3%. In 4 of the 15 patients, CT findings were also suggestive of the primary cancer but were nonetheless equivocal. In these patients, ¹⁸F-FDG showed increased ¹⁸F-FDG uptake by the primary tumour, which was confirmed by histology. One patient had recurrence of breast carcinoma that could not be detected with ¹⁸F-FDG PET, but was detected by CT. In three cases, the primary cancer could not be found with any imaging method. Among the 24 patients in group II investigated for staging purposes, ¹⁸F-FDG PET detected a total of 13 local and three distant lymph node metastases, whereas the conventional imaging methods detected only nine local and one distant lymph node metastases. The results of ¹⁸F-FDG PET led to an upstaging in 5/24 (20.8%) patients. The conventional imaging methods were false positive in 5/24 (20.8%). There was one false positive result using ¹⁸F-FDG PET. Among the 15 patients of group III with suspected recurrence after radiotherapy and/or chemotherapy, ¹⁸F-FDG was true positive in 7/15 (46.6%) and true negative in 4/15 (26.6%). The conventional imaging methods were true positive in 5/15 (33.3%) and true negative in 4/15 (26.6%). One false negative (6.6%) and three false positive findings (20%) on ¹⁸F-FDG PET were due to inflamed tissue. The conventional imaging methods were false positive in three (20%) and false negative in three cases (20%). It is concluded that in comparison to conventional diagnostic methods, ¹⁸F-FDG PET provides additional and clinically relevant information in the detection of primary and metastatic carcinomas as well as in the early detection of recurrent or persistent head and neck cancer after radiotherapy and/or chemotherapy. ¹⁸F-FDG PET should therefore be performed early in clinical routine, usually before CT or MRI.     

18F-FDG PET对原发性食管癌和复发性食管癌的诊断价值

食管癌的预后较差,手术的致死率和致残率均较高,术前正确分期对确定治疗方案显得尤为重要.PET是继CT、MRI、食管镜等常规检查的有益补充.受分辨率的影响,PET较难确定肿瘤的局部浸润程度,在局部淋巴结转移方面其价值有待于进一步的研究,但对远处转移灶的诊断明显优于CT、MRI等常规检查,诊断复发性食管癌准确率较高,能有效鉴别手术疤痕和复发,有效评价放化疗的疗效.结合传统影像学检查,18F-FDG能较为准确地进行术前分期,纠正不正确的治疗方案,改善食管癌的预后.     

18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值

目的 探讨18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值。 方法 对38例临床怀疑为乳腺癌的女性患者于一周内分别行18F-FDG PET/CT、3.0T MRI和病理学检查。 结果 组织病理学检查结果证实,全部患者中,24例为乳腺癌患者,14例为乳腺良性肿瘤患者。3.0T MRI诊断乳腺癌的灵敏度、特异度、准确率分别为91.7%、78.6%、86.8%;PET/CT诊断乳腺癌的灵敏度、特异度、准确率分别为87.5%、92.9%、89.5%;PET/CT和3.0T MR联合显像诊断乳腺癌的灵敏度、特异度、准确率分别为100.0%、92.9%、97.4%;3种显像方法间灵敏度、特异度、准确率差异无统计学意义（χ2=2.987、1.612和2.955,P均＞0.05）。 结论 18F-FDG PET/CT和3.0T MRI联合显像在乳腺癌原发病灶诊断中具有重要价值;但与单独18F-FDG PET/CT和3.0T MRI显像比较,3种显像方法在乳腺癌原发病灶的诊断效能上差异无统计学意义。     

Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.

Chemotherapy is currently the treatment of choice for patients with high-risk metastatic breast cancer. Clinical response is determined after several cycles of chemotherapy by changes in tumor size as assessed by conventional imaging procedures including CT, MRI, plain film radiography, or ultrasound. The aim of this study was to evaluate the use of sequential 18F-FDG PET to predict response after the first and second cycles of standardized chemotherapy for metastatic breast cancer. METHODS: Eleven patients with 26 metastatic lesions underwent 31 (18)F-FDG PET examinations (240-400 MBq of 18F-FDG; 10-min 2-dimensional emission and transmission scans). Clinical response, as assessed by conventional imaging after completion of chemotherapy, served as the reference. 18F-FDG PET images after the first and second cycles of chemotherapy were analyzed semiquantitatively for each metastatic lesion using standardized uptake values (SUVs) normalized to patients' blood glucose levels. In addition, whole-body 18F-FDG PET images were viewed for overall changes in the 18F-FDG uptake pattern of metastatic lesions within individual patients and compared with conventional imaging results after the third and sixth cycles of chemotherapy. RESULTS: After completion of chemotherapy, 17 metastatic lesions responded, as assessed by conventional imaging procedures. In those lesions, SUV decreased to 72% +/- 21% after the first cycle and 54% +/- 16% after the second cycle, when compared with the baseline PET scan. In contrast, 18F-FDG uptake in lesions not responding to chemotherapy (n = 9) declined only to 94% +/- 19% after the first cycle and 79% +/- 9% after the second cycle. The differences between responding and nonresponding lesions were statistically significant after the first (P = 0.02) and second (P = 0.003) cycles. Visual analysis of 18F-FDG PET images correctly predicted the response in all patients as early as after the first cycle of chemotherapy. As assessed by 18F-FDG PET, the overall survival in nonresponders (n = 5) was 8.8 mo, compared with 19.2 mo in responders (n = 6). CONCLUSION: In patients with metastatic breast cancer, sequential 18F-FDG PET allowed prediction of response to treatment after the first cycle of chemotherapy. The use of 18F-FDG PET as a surrogate endpoint for monitoring therapy response offers improved patient care by individualizing treatment and avoiding ineffective chemotherapy.     

Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.

This prospective study was designed to assess the utility of the dual time point imaging technique by (18)F-FDG PET in detecting primary breast cancer and to determine whether there is a relationship between (18)F-FDG uptake and its change over time and the histopathologic subtypes. METHODS: One hundred fifty-two patients with newly diagnosed breast cancer underwent 2 sequential PET scans (dual time point imaging) for preoperative staging. The maximum standardized uptake value (SUVmax) of (18)F-FDG was measured from both time points. The percent change in SUVmax (Delta%SUVmax) between time points 1 (SUVmax1) and 2 (SUVmax2) was calculated. Patients were divided into 2 groups according to histopathology as invasive and noninvasive. Invasive tumors were also divided into 2 groups (>10 mm and 4-10 mm). The tumor-to-contralateral normal breast (background) ratios of SUVmax at both time points for groups were measured and the Delta%SUVmax values were calculated. RESULTS: The mean +/- SD of the SUVmax1, the SUVmax2, and the Delta%SUVmax were 3.9 +/- 3.7, 4.3 +/- 4.0, and 8.3% +/- 11.5% for invasive; 2.0 +/- 0.6, 2.1 +/- 0.6, and 3.4% +/- 13.0% for noninvasive; and were 1.2 +/- 0.3, 1.1 +/- 0.2, and -10.0% +/- 10.8% for the contralateral normal breast groups, respectively. In the comparison of SUVmax1, Delta%SUVmax, and the tumor-to-background ratios among groups, all results were significant (P < 0.001). Visual assessment revealed that the sensitivity of dual time point imaging was 90.1% for invasive cancer >10 mm, 82.7% for invasive breast cancers 4-10 mm, and 76.9% for noninvasive breast cancers. CONCLUSION: Dual time point imaging is a simple and noninvasive method that may improve the sensitivity and accuracy of (18)F-FDG PET in assessing patients with primary breast cancer. The changes that are noted in SUVs in dual time point imaging vary depending on the histopathologic type of primary breast cancer.     

PET/CT在乳腺癌疗效监测中的作用

18F-FDG PET集合了形态学与功能学成像的优势,可通过观察肿瘤细胞内FDG的浓聚程度变化来评价药物治疗的效果,因此在乳腺癌新辅助化疗(NAC)及复发/转移性乳腺癌的综合治疗中颇受关注。本文就18FFDG PET/CT在乳腺癌NAC及复发/转移性乳腺癌治疗中的作用进行总结,同时对近期较受关注的新型显像方式,如雌激素受体显像、细胞乏氧显像、细胞增殖显像、Her-2/neu显像等在乳腺癌中的应用进行归纳及展望。